Novo Nordisk Plans NovoLog Mix Marketing Around Glycemic Control Benefits
This article was originally published in The Pink Sheet Daily
Dosing may be less convenient, but pre-mixed product provides better diabetes control than once-daily injections like Sanofi-Aventis' Lantus, Novo Nordisk CEO Sorensen maintains. The company expects approval of its long-acting insulin Levemir in the third quarter of 2005.
You may also be interested in...
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).